Sunday 9 August 2026

The Pharma Letter Podcast — Episode 6 — Patient empowerment and multiple sclerosis

Pharmaceutical
Simon Wentworth
1 November 2021
janssen_podcast

More on this story...

Biotechnology
Multiple sclerosis treatment fails to impress in mid-stage trial
21 March 2022
Biotechnology
F-star Therapeutics bags $1.5 billion deal with Janssen
20 October 2021
Biotechnology
Janssen receives MHRA authorization for Ponvory in RMS
11 August 2021
Biotechnology
Mestag teams up with Janssen in inflammatory disease
18 May 2021


Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

The week in pharma: action, reaction and insight – week to August 7, 2026
Pharmaceutical
The week in pharma: action, reaction and insight – week to August 7, 2026
9 August 2026
Pharmaceutical
Astellas files NDA for fezolinetant in Japan
8 August 2026
Pharmaceutical
Wasted medicines costing England’s NHS £480 million+
8 August 2026
Pharmaceutical
China approval for TransThera’s Yochanra
7 August 2026
Biosimilars
Biocon announces commercial launch of Yesafili in USA
7 August 2026
Pharmaceutical
Tarsus to acquire Alkeus Pharma, adding retina repertoire
7 August 2026
Pharmaceutical
AI and patents: does AI make everything obvious?
7 August 2026


Company Spotlight

Attovia Therapeutics
A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus.


More Features in Pharmaceutical

The week in pharma: action, reaction and insight – week to August 7, 2026
9 August 2026
Astellas files NDA for fezolinetant in Japan
8 August 2026
Wasted medicines costing England’s NHS £480 million+
8 August 2026
China approval for TransThera’s Yochanra
7 August 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze